ANI PHARMACEUTICALS INC (ANIP)
Health Care · Specialty pharmaceuticals and generic pharmaceutical manufacturing · NASDAQ
Diversified specialty pharmaceutical company manufacturing branded rare-disease and ophthalmology products alongside a portfolio of 120+ generic pharmaceuticals.
What ANI PHARMACEUTICALS INC does
ANI Pharmaceuticals is a diversified bio-pharmaceutical company that develops, manufactures, and commercializes therapeutics across three segments: Rare Disease, Generics, and Brands. The company operates three pharmaceutical manufacturing facilities capable of producing oral solids, semi-solids, liquids, topicals, controlled substances, and potent products. Its portfolio includes over 120 generic products, branded therapies like Cortrophin Gel and ILUVIEN (for diabetic macular edema and non-infectious uveitis), and a robust pipeline expected to launch 10–15 new products annually.
Themes: ["Rare disease / specialty pharmaceuticals","Generic pharmaceuticals","Ophthalmology / retinal disease","Autoimmune disease treatment","Pharmaceutical manufacturing"]
Fundamentals
- Price$83.78 as of 2026-07-09 close
- Market cap$1.9B as of 2026-07-10
- 1-year return+28.3% as of 2026-07-09 close
- P/E20.88 as of 2026-07-10
- Net margin+10.0% as of 2026-07-10
- Gross margin+60.8% as of 2026-07-10
- ROE+17.8% as of 2026-07-10
- Debt / equity1.09 as of 2026-07-10
- Revenue growth (YoY)+37.0% as of 2026-07-10
- Revenue CAGR (3y)+40.8% SEC XBRL
- Beta0.47 as of 2026-07-10
Dividend: yield +0.0%; pays a dividend.
Key risks (from latest filing)
["Significant competition and rapidly changing market environment; success of competing therapies may impact product acceptance and pricing power","Manufacturing and regulatory compliance risks across three operating facilities; reliance on third-party suppliers for critical raw materials and contract manufacturing services","Integration risks and debt burden from Alimera acquisition ($325M term loan and $316.25M convertible notes due 2029) may impact financial flexibility and profitability"]
Competitors & peers
- Teva Pharmaceutical Industries
- Mallinckrodt Pharmaceuticals
- Bausch + Lomb (eye care and ophthalmology)
- Allergan (now AbbVie specialty care)
- Sun Pharmaceutical
- Apotex
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.